Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-052-4
CAS number: 102-77-2
Nominal concentrations: 0, 0.068, 0.168, 0.53 mg/l
Mean analytical concentrations: 0.0044, 0.0098, 0.0102 mg/l
Gravimetric concentrations: 0, 0.0043, 0.0097, 0.0103 mg/l
Dust particle size distribution analyses:
the equivalent aerodynamic diameter: 9.8 µm, geometric standard
Appearance and general behavior:
The rats exhibited occational nasal irritation which appeared to be
concentration related. Nasal irritation was observed afterexposure but
was usually not observed the following morning. Several rats exhibited
skin irritation in the form of alopecia which did not appear to be
Body weights: females no effects, males a slight decrease in body weight
was noted in treated males of the highest dose group (ca. 92 %) compared
Food consumption: no time or test substance related differences were
Hematology: no effects
In males and females of all treatment groups: the SGOT values were
significant elevated and the blood glucose was significant decreased
when compared to control (II). The effect did not appear to be
concentration related for either parameter.
All other parameters appeared comparable to both controls.
Urinalysis: no effects
No gross lesions interpreted as compound induced observation in any
animal at necropsy.
Some variations in absolute and
rel. organ weights were noted, but the variations did not appear to be
dose dependent, except for males of the highest dose group which showed
a decrease in rel. and absolute lung weights (ca. 20 % absolute lung
weights, rel weights ca. 13 % compared to control I and II)
No microscopic lesions interpreted as compound related were observed in
any tissues examined from rats of the highest dose group.
Focal/multifocal mineralization was present in stomach, duodenum, colon,
urinary bladder, meninges, eye, kidneys, liver, heart and lung ofsome
animals which had inhaled 0.5 mg/ml (corresponding to mean analytical
concentration of 0.0102 mg/ml). The distribution of the mineral in the
affected tissues was simular to that observed in control I; however ,
the incidence and severity of the lesion was reduced when compared to
control I. Mineral was not always present in all the above tissues from
the same animal, however it appeared that only the last 5 males and
females in the numerical sequene were involved. The occurence and
incidence of all other microscopic lesions were simular to that observed
in control I and II. Common microscopic lesions interpreted as primarily
inflammatory in nature involved trachea (mononuclear infiltrate),
prostate (prostatitis), meninges, (mononuclear infiltrate), kidneys
(subacute/chronic neprhitis), liver (parenchymal/periportal mononuclear
infiltrate), heart (mononuclear inflammatory infiltrate) and lungs
(peribronchiolar lymphiod hyperplasia, perivascular mononuclear
infiltrate). Common non-inflammatory lesions observed thyroids
(ultimobranchial rests) uterus (hypromatra), lymph nodes (brown pigment
in sinusoidal macrophages, erythrophagocytosis), kidneys of male rats
(proteinaceous material within renal tubules), liver(acidophilic
degeneration of hepatocytes, bile duct hyperplasia, portal fibrosis) and
lungs (multifocal acute hemorrhages).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again